The Added Value of 166Ho Trans-arterial Radioembolization to Systemic Therapy in Liver Metastatic Breast Cancer Patients
The goal of this multicentre clinical pilot study is to investigate the feasibility of the addition of Ho-166 radioembolization to chemotherapy in patients with liver metastastic breast cancer. Participants will receive a mapping angiography and Ho-166 radioembolization. Chemotherapy will be stopped 2-5 prior to radioembolization and continuation of chemotherapy will be evaluated at 2 weeks post-radioembolization.
• Women \>18 years
• Patients with hormone positive and HER2 negative liver metastatic breast cancer
• No extra-hepatic disease progression at evaluation of at least second line systemic chemotherapy
• Suitable for TARE evaluated after the mapping angiography
• Measurable target tumors in the liver according to RECIST 1.1
• Liver tumor burden \<50 %
• ECOG performance score 0 to 1
• Laboratory parameters: neutrophils \>1000/μL; thrombocyte count \>1000000 μL; eGFR \>45/mL/min/1.73 m2; albumin \> 3.0 g/dl, bilirubin \< 1.5x ULN (unless Gilbert syndrome); aminotransferase (ALAT/ASAT) \<3.0 ULN
• Able to read Dutch